On October 3 Maxim Stetsyuk, Executive Director of NANOLEK, became a participant in the XI International Conference “What is happening on the pharmaceutical market?”.
The conference is the main meeting place for the main players of the pharmaceutical community: heads of representative offices, general directors and top managers of pharmaceutical manufacturers, distributors and retailers, heads of associations, representatives of regulators, professional and business media.
Maxim Stetsyuk took part in the session “A labeling of medicines again. And questions again. ” Experts from FEDERAL SERVICE FOR SURVEILLANCE IN HEALTHCARE, as well as top managers of pharmaceutical companies, distributors and pharmacy chains talked about practical experience in introducing labeling, the readiness of the entire supply chain for implementation, the main problems of drug manufacturers and equipment manufacturers, the possible introduction of fines for the sale of drugs without labeling, etc.
“The company NANOLEK has installed the necessary equipment and now we are at the stage of active testing of the test period. On October 2019, we will begin to mark the first orphan drug.
In order for the whole system to work properly, the process of forming interaction with other participants in the system is necessary (manufacturer - distributor - pharmacy - manufacturer of healthcare facilities), with the scaling of all processes, these problems can turn into serious failures. This must be taken into account and an adequate response system developed, including at the legislative level with the assignment of statuses and certain decisions in a given situation.
In anticipation of labeling, two main things need to be done: the regulator to interview all the major market participants about their readiness and, based on the results of the survey, issue the relevant instructions,” commented by Maxim Stetsyuk.
